A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
NCT04072900
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Melanoma (Skin)
Interventions
DRUG:
Peptide
DRUG:
Anti-PD-1
DRUG:
rhGM-CSF
DRUG:
Imiquimod 5% Topical Cream
Sponsor
Xiangya Hospital of Central South University